-DOCSTART- -X- O
Several -X- _ O
mouse -X- _ O
models -X- _ O
of -X- _ O
multiple -X- _ O
sclerosis -X- _ O
( -X- _ O
MS -X- _ O
) -X- _ O
are -X- _ O
now -X- _ O
available. -X- _ O
We -X- _ O
have -X- _ O
established -X- _ O
a -X- _ O
mouse -X- _ B-Patient
model -X- _ I-Patient
, -X- _ O
in -X- _ O
which -X- _ O
ocular -X- _ B-Outcome
infection -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
recombinant -X- _ I-Outcome
HSV-1 -X- _ I-Outcome
that -X- _ I-Outcome
expresses -X- _ I-Outcome
murine -X- _ I-Outcome
IL-2 -X- _ I-Outcome
constitutively -X- _ I-Outcome
( -X- _ I-Outcome
HSV-IL-2 -X- _ I-Outcome
) -X- _ I-Outcome
causes -X- _ I-Outcome
CNS -X- _ I-Outcome
demyelination -X- _ I-Outcome
in -X- _ I-Outcome
different -X- _ I-Outcome
strains -X- _ I-Outcome
of -X- _ I-Outcome
mice. -X- _ I-Outcome
This -X- _ I-Outcome
model -X- _ I-Outcome
differs -X- _ I-Outcome
from -X- _ I-Outcome
most -X- _ I-Outcome
other -X- _ I-Outcome
models -X- _ I-Outcome
in -X- _ I-Outcome
that -X- _ I-Outcome
it -X- _ I-Outcome
represents -X- _ I-Outcome
a -X- _ I-Outcome
mixture -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
and -X- _ I-Outcome
immune -X- _ I-Outcome
triggers. -X- _ I-Outcome
In -X- _ O
the -X- _ O
present -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
directly -X- _ O
compared -X- _ O
MOG -X- _ B-Comparison
( -X- _ I-Comparison
35–55 -X- _ I-Comparison
) -X- _ I-Comparison
, -X- _ I-Comparison
MBP -X- _ I-Comparison
( -X- _ I-Comparison
35–47 -X- _ I-Comparison
) -X- _ I-Comparison
, -X- _ I-Comparison
and -X- _ I-Comparison
PLP -X- _ I-Comparison
( -X- _ I-Comparison
190–209 -X- _ I-Comparison
) -X- _ I-Comparison
models -X- _ I-Comparison
of -X- _ I-Comparison
EAE -X- _ I-Comparison
with -X- _ O
our -X- _ O
HSV-IL-2-induced -X- _ B-Intervention
MS -X- _ I-Intervention
model. -X- _ I-Intervention
Mice -X- _ B-Outcome
with -X- _ I-Outcome
HSV-IL-2-induced -X- _ I-Outcome
and -X- _ I-Outcome
MOG-induced -X- _ I-Outcome
demyelinating -X- _ I-Outcome
diseases -X- _ I-Outcome
demonstrated -X- _ I-Outcome
a -X- _ I-Outcome
similar -X- _ I-Outcome
pattern -X- _ I-Outcome
and -X- _ I-Outcome
distribution -X- _ I-Outcome
of -X- _ I-Outcome
demyelination -X- _ I-Outcome
in -X- _ I-Outcome
their -X- _ I-Outcome
brain -X- _ I-Outcome
, -X- _ I-Outcome
spinal -X- _ I-Outcome
cord -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
optic -X- _ I-Outcome
nerves. -X- _ I-Outcome
In -X- _ I-Outcome
contrast -X- _ I-Outcome
, -X- _ I-Outcome
no -X- _ I-Outcome
demyelination -X- _ I-Outcome
was -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
optic -X- _ I-Outcome
nerves -X- _ I-Outcome
of -X- _ I-Outcome
MBP- -X- _ I-Outcome
and -X- _ I-Outcome
PLP-injected -X- _ I-Outcome
mice. -X- _ I-Outcome
IFN-β -X- _ I-Outcome
injections -X- _ I-Outcome
significantly -X- _ I-Outcome
reduced -X- _ I-Outcome
demyelination -X- _ I-Outcome
in -X- _ I-Outcome
brains -X- _ I-Outcome
of -X- _ I-Outcome
all -X- _ I-Outcome
groups -X- _ I-Outcome
, -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
spinal -X- _ I-Outcome
cords -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
MOG -X- _ I-Outcome
and -X- _ I-Outcome
MBP -X- _ I-Outcome
groups -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
completely -X- _ I-Outcome
blocked -X- _ I-Outcome
it -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
spinal -X- _ I-Outcome
cords -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
PLP -X- _ I-Outcome
and -X- _ I-Outcome
HSV-IL-2 -X- _ I-Outcome
groups -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
in -X- _ I-Outcome
optic -X- _ I-Outcome
nerves -X- _ I-Outcome
of -X- _ I-Outcome
MOG -X- _ I-Outcome
and -X- _ I-Outcome
HSV-IL-2 -X- _ I-Outcome
groups. -X- _ I-Outcome
In -X- _ I-Outcome
contrast -X- _ I-Outcome
to -X- _ I-Outcome
IFN-β -X- _ I-Outcome
treatment -X- _ I-Outcome
, -X- _ I-Outcome
IL-12p70 -X- _ I-Outcome
protected -X- _ I-Outcome
the -X- _ I-Outcome
HSV-IL-2 -X- _ I-Outcome
group -X- _ I-Outcome
from -X- _ I-Outcome
demyelination -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
IL-4 -X- _ I-Outcome
was -X- _ I-Outcome
not -X- _ I-Outcome
effective -X- _ I-Outcome
at -X- _ I-Outcome
all -X- _ I-Outcome
in -X- _ I-Outcome
preventing -X- _ I-Outcome
demyelination. -X- _ I-Outcome
MOG-injected -X- _ I-Outcome
mice -X- _ I-Outcome
showed -X- _ I-Outcome
clinical -X- _ I-Outcome
signs -X- _ I-Outcome
of -X- _ I-Outcome
paralysis -X- _ I-Outcome
and -X- _ I-Outcome
disease-related -X- _ I-Outcome
mortality -X- _ I-Outcome
whereas -X- _ I-Outcome
mice -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
other -X- _ I-Outcome
treatment -X- _ I-Outcome
groups -X- _ I-Outcome
did -X- _ I-Outcome
not. -X- _ I-Outcome
Collectively -X- _ O
, -X- _ O
the -X- _ O
results -X- _ O
indicate -X- _ O
that -X- _ O
the -X- _ O
HSV-IL-2 -X- _ O
model -X- _ O
and -X- _ O
the -X- _ O
MOG -X- _ O
model -X- _ O
complement -X- _ O
each -X- _ O
other -X- _ O
and -X- _ O
, -X- _ O
together -X- _ O
, -X- _ O
provide -X- _ O
unique -X- _ O
insights -X- _ O
into -X- _ O
the -X- _ O
heterogeneity -X- _ O
of -X- _ O
human -X- _ O
MS -X- _ O
. -X- _ O

